MX387590B - Compuestos policíclicos como inhibidores de tirosina quinasa de bruton. - Google Patents

Compuestos policíclicos como inhibidores de tirosina quinasa de bruton.

Info

Publication number
MX387590B
MX387590B MX2018007075A MX2018007075A MX387590B MX 387590 B MX387590 B MX 387590B MX 2018007075 A MX2018007075 A MX 2018007075A MX 2018007075 A MX2018007075 A MX 2018007075A MX 387590 B MX387590 B MX 387590B
Authority
MX
Mexico
Prior art keywords
bruton
kinase inhibitors
tyrosine kinase
polycyclic compounds
compounds
Prior art date
Application number
MX2018007075A
Other languages
English (en)
Spanish (es)
Other versions
MX2018007075A (es
Inventor
Genesis M Bacani
Scott D Bembenek
Brahmananda Ghosh
Wei Chen
Charlotte Pooley Deckhut
James P Edwards
Feihuang Zhang
Gang Li
Joseph Kent Barbay
Kevin Kreutter
Min Cai
Nidhi Arora
Mark S Tichenor
Jennifer D Venable
Jianmei Wei
John J M Wiener
Kun Xiao
Yao Wu
Yaoping Zhu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2018007075A publication Critical patent/MX2018007075A/es
Publication of MX387590B publication Critical patent/MX387590B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018007075A 2015-12-10 2016-12-09 Compuestos policíclicos como inhibidores de tirosina quinasa de bruton. MX387590B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562265836P 2015-12-10 2015-12-10
PCT/US2016/065954 WO2017100662A1 (en) 2015-12-10 2016-12-09 Polycyclic compounds as inhibitors of bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
MX2018007075A MX2018007075A (es) 2018-11-09
MX387590B true MX387590B (es) 2025-03-18

Family

ID=57681784

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007075A MX387590B (es) 2015-12-10 2016-12-09 Compuestos policíclicos como inhibidores de tirosina quinasa de bruton.

Country Status (30)

Country Link
US (5) US10717745B2 (enExample)
EP (2) EP3386991B1 (enExample)
JP (2) JP6835846B2 (enExample)
KR (1) KR102103395B1 (enExample)
CN (2) CN108884106A (enExample)
AR (1) AR107042A1 (enExample)
AU (1) AU2016366541B2 (enExample)
BR (1) BR112018011526B1 (enExample)
CA (1) CA3007990C (enExample)
CY (1) CY1123263T1 (enExample)
DK (1) DK3386991T3 (enExample)
EA (1) EA035168B1 (enExample)
ES (1) ES2805835T3 (enExample)
HR (1) HRP20201193T1 (enExample)
HU (1) HUE049502T2 (enExample)
IL (1) IL259863B (enExample)
JO (1) JO3794B1 (enExample)
LT (1) LT3386991T (enExample)
MA (2) MA43409B1 (enExample)
MD (1) MD3386991T2 (enExample)
ME (1) ME03803B (enExample)
MX (1) MX387590B (enExample)
PL (1) PL3386991T3 (enExample)
PT (1) PT3386991T (enExample)
RS (1) RS60604B1 (enExample)
SI (1) SI3386991T1 (enExample)
SM (1) SMT202000404T1 (enExample)
TW (1) TWI729047B (enExample)
UY (1) UY37015A (enExample)
WO (1) WO2017100662A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
WO2018170220A1 (en) * 2017-03-15 2018-09-20 Janssen Sciences Ireland Uc Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
EP4089095A4 (en) * 2020-01-07 2024-03-27 Medshine Discovery Inc. DEUTERATED THIENOPYRIDINE COMPOUND
EP4301365A1 (en) * 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
MX2023014435A (es) 2021-06-04 2024-03-08 Janssen Pharmaceutica Nv Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
MX2023015147A (es) * 2021-06-30 2024-04-01 Janssen Pharmaceutica Nv Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
WO2023016995A1 (en) 2021-08-09 2023-02-16 Janssen Pharmaceutica Nv Compositions for use in treating b-cell malignancies
MX2024010134A (es) * 2022-02-18 2024-08-27 Janssen Pharmaceutica Nv Sintesis de inhibidores de tirosina quinasa de bruton.
WO2025262118A1 (en) 2024-06-20 2025-12-26 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
AU2005284796A1 (en) 2004-09-15 2006-03-23 Janssen Pharmaceutica, N.V. Thiazolopyridine kinase inhibitors
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
US7605154B2 (en) 2005-08-08 2009-10-20 Janssen Pharmaceutica N.V. Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
US7427625B2 (en) * 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2010056875A1 (en) * 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
EP2471789B9 (en) * 2009-08-26 2015-03-25 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
EP2970291B1 (en) 2013-03-15 2022-05-11 Janssen Pharmaceutica, N.V. Processes and intermediates for preparing a medicament
HRP20181109T1 (hr) * 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
SMT202000404T1 (it) 2020-09-10
BR112018011526B1 (pt) 2024-02-27
NZ742484A (en) 2021-09-24
JP6835846B2 (ja) 2021-02-24
CA3007990C (en) 2024-01-02
KR20180093974A (ko) 2018-08-22
US20190276471A1 (en) 2019-09-12
CN113121562B (zh) 2022-09-13
EP3719022B1 (en) 2026-07-08
CN108884106A (zh) 2018-11-23
IL259863A (en) 2018-07-31
US20230097422A1 (en) 2023-03-30
BR112018011526A2 (pt) 2018-11-21
EA035168B1 (ru) 2020-05-08
AU2016366541B2 (en) 2021-05-13
LT3386991T (lt) 2020-08-25
RS60604B1 (sr) 2020-08-31
PL3386991T3 (pl) 2021-03-08
SI3386991T1 (sl) 2020-08-31
TW201734021A (zh) 2017-10-01
CA3007990A1 (en) 2017-06-15
PT3386991T (pt) 2020-08-18
JO3794B1 (ar) 2021-01-31
HUE049502T2 (hu) 2020-09-28
TWI729047B (zh) 2021-06-01
EA201891378A1 (ru) 2018-12-28
JP2021073286A (ja) 2021-05-13
IL259863B (en) 2020-06-30
UY37015A (es) 2017-06-30
ME03803B (me) 2021-04-20
WO2017100662A1 (en) 2017-06-15
CN113121562A (zh) 2021-07-16
KR102103395B1 (ko) 2020-04-23
AR107042A1 (es) 2018-03-14
US20210101910A1 (en) 2021-04-08
EP3719022A1 (en) 2020-10-07
MA43409B1 (fr) 2020-10-28
JP7072690B2 (ja) 2022-05-20
EP3386991A1 (en) 2018-10-17
US20240383914A1 (en) 2024-11-21
US11319329B2 (en) 2022-05-03
HRP20201193T1 (hr) 2020-11-13
ES2805835T3 (es) 2021-02-15
US12065446B2 (en) 2024-08-20
US20170283430A1 (en) 2017-10-05
DK3386991T3 (da) 2020-07-13
CY1123263T1 (el) 2021-12-31
US10934310B2 (en) 2021-03-02
JP2018536686A (ja) 2018-12-13
AU2016366541A1 (en) 2018-05-31
MX2018007075A (es) 2018-11-09
EP3386991B1 (en) 2020-06-03
MD3386991T2 (ro) 2020-11-30
US10717745B2 (en) 2020-07-21
MA53110A (fr) 2021-05-12

Similar Documents

Publication Publication Date Title
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
MX386700B (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX385082B (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
CR20190566A (es) Inhibidores de quinasay usos de los mismos
MX2019001096A (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
MX390347B (es) Compuestos de aminotiazol como inhibidores de c-kit.
EA201892147A1 (ru) Бициклические соединения
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
MX2017014459A (es) Compuestos de tioeter como inhibidores de la nitrificacion.
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
EA201690844A1 (ru) Ингибиторы gsk-3
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
MX2017003254A (es) 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
MX2019007571A (es) Polimorfos.
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
EA201692289A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
MX376059B (es) Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk).
EA201501175A1 (ru) Новые соединения для лечения злокачественного новообразования
MX2020006016A (es) Polimorfos.